Baird Medical Investment Holdings Limited Cash Flow Conversion Efficiency
Baird Medical Investment Holdings Limited cash flow conversion efficiency. Based on the latest financial reports, Baird Medical Investment Holdings Limited (BDMD) has a cash flow conversion efficiency ratio of -0.090x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.19 Million) by net assets ($35.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Baird Medical Investment Holdings Limited (2019–2024)
Cash flow conversion efficiency of Baird Medical Investment Holdings Limited from 2019 to 2024. This chart illustrates how Baird Medical Investment Holdings Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BDMD stock price and chart for real-time trading data and today's change.
Baird Medical Investment Holdings Limited Cash Flow Conversion Ratio Explained
Baird Medical Investment Holdings Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Baird Medical Investment Holdings Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Baird Medical Investment Holdings Limited ranked by their cash flow conversion efficiency. Also see BDMD market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pacte Novation
PA:MLPAC
|
N/A |
|
E. Pairis S.A
AT:PAIR
|
0.051x |
|
Sequa Petroleum NV
PA:MLSEQ
|
0.008x |
|
Kontigo Care AB
ST:KONT
|
0.046x |
|
Akash Infra-Projects Limited
NSE:AKASH
|
0.021x |
|
CC Japan Income and Growth Trust PLC
LSE:CCJI
|
-0.007x |
|
Mask Investments Limited
NSE:MASKINVEST
|
-0.002x |
|
Project Planning Service Public Company Limited
BK:PPS
|
-0.045x |
Annual Cash Flow Conversion Efficiency for Baird Medical Investment Holdings Limited (2019–2024)
The table below shows the annual cash flow conversion efficiency of Baird Medical Investment Holdings Limited from 2019 to 2024. Review Baird Medical Investment Holdings Limite free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $39.76 Million | $-6.31 Million | -0.159x | -455.86% |
| 2023-12-31 | $35.71 Million | $-1.02 Million | -0.029x | -251.52% |
| 2022-12-31 | $25.78 Million | $485.97K | 0.019x | -94.31% |
| 2021-12-31 | $15.86 Million | $5.26 Million | 0.331x | -42.65% |
| 2020-12-31 | $6.76 Million | $3.91 Million | 0.578x | +395.65% |
| 2019-12-31 | $-22.58 Million | $4.41 Million | -0.195x | -- |
About Baird Medical Investment Holdings Limited
Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; long microwave ablation needles; and fine microwave ablation needles for the treatment of benign and malignant tumors, in… Read more